Fulgent Genetics (FLGT) Stock Price, News & Analysis

Company Overview

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Key Stats

• Today's Range: $18.56 to $19.72
• 50-Day Range: $16.65 to $20.54
• 52-Week Range: $14.57 to $25.11
• Volume: 369,014 shs
• Average Volume: 270,920 shs
• Market Capitalization: $603.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.00
• Consensus Rating: Moderate Buy

Fulgent Genetics Stock Analysis - MarketRank™

Fulgent Genetics scored higher than 67% of companies evaluated by MarketBeat, and ranked 320th out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Fulgent Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Fulgent Genetics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Fulgent Genetics are expected to decrease in the coming year, from ($0.85) to ($1.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fulgent Genetics is -3.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fulgent Genetics is -3.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Fulgent Genetics has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.85% of the float of Fulgent Genetics has been sold short.

Short Interest Ratio / Days to Cover

Fulgent Genetics has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Fulgent Genetics has recently increased by 15.79%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fulgent Genetics does not currently pay a dividend.

Dividend Growth

Fulgent Genetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -0.67

Percentage of Shares Shorted

8.85% of the float of Fulgent Genetics has been sold short.

Short Interest Ratio / Days to Cover

Fulgent Genetics has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Fulgent Genetics has recently increased by 15.79%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.81

News Sentiment

Fulgent Genetics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Fulgent Genetics this week, compared to 2 articles on an average week.

Search Interest

Only 9 people have searched for FLGT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Fulgent Genetics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,596,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

33.11% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

48.06% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FLGT Stock Analysis - Frequently Asked Questions

How have FLGT shares performed this year?

Fulgent Genetics' stock was trading at $18.47 at the beginning of the year. Since then, FLGT shares have increased by 5.8% and is now trading at $19.55.
View the best growth stocks for 2025 here.

How were Fulgent Genetics' earnings last quarter?

Fulgent Genetics, Inc. (NASDAQ:FLGT) released its earnings results on Friday, May, 2nd. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.22. The firm's revenue was up 14.0% compared to the same quarter last year.
Read the conference call transcript.

Does Fulgent Genetics have any subsidiaries?

Fulgent Genetics subsidiaries include these companies: Inform Diagnostics, CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, and Fulgent Therapeutics LLC.

When did Fulgent Genetics IPO?

Fulgent Genetics (FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Who are Fulgent Genetics' major shareholders?

Fulgent Genetics' top institutional investors include Vanguard Group Inc. (3.78%), Deutsche Bank AG (0.87%), Charles Schwab Investment Management Inc. (0.79%) and Peapod Lane Capital LLC (0.53%). Insiders that own company stock include Hanlin Gao, Ming Hsieh, Paul Kim and Jian Xie.
View institutional ownership trends.

How do I buy shares of Fulgent Genetics?

Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Fulgent Genetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fulgent Genetics investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Meta Platforms (META), Advanced Micro Devices (AMD), PayPal (PYPL), Broadcom (AVGO) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/02/2025
• Today: 5/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:FLGT
• CIK: 1674930
• Web: www.fulgentgenetics.com
• Phone: (626) 350-0537
• Fax: 626-454-1667
• Employees: 1,010
• Year Founded: 2011

Price Target and Rating

• Average Stock Price Target: $24.00
• High Stock Price Target: $25.00
• Low Stock Price Target: $23.00
• Potential Upside/Downside: +22.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-167,820,000.00
• Net Margins: -59.39%
• Pretax Margin: -68.09%
• Return on Equity: -1.81%
• Return on Assets: -1.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.41
• Quick Ratio: 4.41

Sales & Book Value

• Annual Sales: $292.45 million
• Price / Sales: 2.06
• Cash Flow: $3.82 per share
• Price / Cash Flow: 5.12
• Book Value: $38.24 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 30,866,000
• Free Float: 20,873,000
• Market Cap: $603.43 million
• Optionable: Optionable
• Beta: 1.00